M Zamorano, B Puerto, J Carceller, J J González-López, M S Figueroa, F J Muñoz-Negrete
{"title":"Atypical presentation of type 1 neovascularization with aneurysmal dilations in a young female.","authors":"M Zamorano, B Puerto, J Carceller, J J González-López, M S Figueroa, F J Muñoz-Negrete","doi":"10.1016/j.oftale.2024.10.004","DOIUrl":null,"url":null,"abstract":"<p><p>Type 1 Neovascularization with Aneurysmal Dilations (N1a), is a retinal disorder characterized by choroidal vascular abnormalities. Clinically, it is characterized by an exudative maculopathy with multiple recurrent serosanguineous pigment epithelial detachments. This disease is more frequent in women aged 55-65 years. However, we present an exceptional case of N1a in a 26-year-old woman, who responded favorably to Aflibercept. To our knowledge, this is the first reported case of a young female patient under 30 with N1a. The patient has responded very favourably to anti-VEGF therapy with three intravitreal injections of Aflibercept. This being the reason for we provide an update on anti-VEGF therapeutic options for N1a.</p>","PeriodicalId":93886,"journal":{"name":"Archivos de la Sociedad Espanola de Oftalmologia","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivos de la Sociedad Espanola de Oftalmologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.oftale.2024.10.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Type 1 Neovascularization with Aneurysmal Dilations (N1a), is a retinal disorder characterized by choroidal vascular abnormalities. Clinically, it is characterized by an exudative maculopathy with multiple recurrent serosanguineous pigment epithelial detachments. This disease is more frequent in women aged 55-65 years. However, we present an exceptional case of N1a in a 26-year-old woman, who responded favorably to Aflibercept. To our knowledge, this is the first reported case of a young female patient under 30 with N1a. The patient has responded very favourably to anti-VEGF therapy with three intravitreal injections of Aflibercept. This being the reason for we provide an update on anti-VEGF therapeutic options for N1a.